Member Info for CrudeTrader

Sharefall, what are you smoking, the meeting in Moscow didnt go great and today its low level people meeting in UAE.

Couerdelion, I have been listening to listed corps calls for +25 year now, the way he responded to the questions is really saying that we are not going to do this project. Remember that when Serica walks in few months time.

Serica held its 2025-year end operational update call today, in the end of the call they were asked what the plan was for Buchana, the company comment was not very supportive for the project. It very much feels like Serica is warming up to ditch the project.

Going from 20.75% to 20.22% yday

Lets hope they wont sell to much more, could create some pressure

"Total revenues for FY25E are expected to be c$50m against our $54.6m estimate, with 4Q25 seeing a reduction in the average net selling price to $222 (4Q24: $237) and total prescriptions for the year coming in at c199,000. While the absolute quantum of commercial sales was lower than we’d hoped in the latter part of the year"

So they have done what they said they would do the testing side. But there is nothing on market attraction / orders. Jam tomorrow forever,.

DEC will make big move very soon now

Always the same:

-> Running out of cash in less than 6 months

-> Clearly no Nasdaq listing, when appointing tiny local broker as NOMAD

-> Partnership discussion sounds uber dull

Not a great read these results

The Americans will take up DEC when the US market opens tomorrow.

I think we will get some profit taking now after it has hit 0.6p. Then it will move higher after the profit taking.

I guess we will get an update on the funding situation as we approach the end of January deadline, based on what was communicated in the recent Prospectus.

What is left to close the deal for WG?

Did we only get a short party this time?

All news sold into

Great outcome for funding, but I suspect the stock will be smacked down in the US as some CB takers will delta hedge by shorting the stock.

TSX close 44 cent -> 23.5p

Same as the 12th Jan update?

Matt5, that amazing, should be quite unique to have resources like that.

Nps4, the company wrote in the prospectus that partnership with bigger pharma companies was mostly dependent on delivering enough safety data. I'm not an exprt on trial saftey, but HEMO is putting this out as key factor of getting traction from big pharma, so I thought it was a valid point.